Published Paper Details:

Migraine is a common neurological condition that can really take a toll on people's quality of life and productivity around the globe. It's marked by recurring headaches that often come with nausea, sensitivity to light, and sensitivity to sound. Traditional preventive treatments, like beta-blockers and antiepileptics, often fall short in terms of effectiveness and tolerability, which is why there's a need for new options. Enter atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist that's making waves in the world of migraine prevention. It got the green light from the FDA in 2021, followed by approvals from Health Canada and the EMA, making it the first oral CGRP antagonist specifically designed for preventing migraines. Atogepant is quickly absorbed, spreads widely in the body, and is mainly broken down by CYP3A4, boasting a half-life of about 11 hours, which allows for once-daily dosing. It works by blocking CGRP-induced vasodilation and neurogenic inflammation, helping to cut down on the frequency and intensity of migraines. Clinical trials have shown it effectively reduces the number of migraine days each month, with some common side effects like constipation, nausea, and fatigue. All in all, atogepant offers a safe, effective, and convenient oral solution, marking a big step forward in personalized migraine management.